Pancreatic Cancer Research

ResearcherUniversity of Southern DenmarkActive in the last 2 years

Per Pfeiffer

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-2925-0586; OpenAlex author ID A5068848511. Sources: ClinicalTrials.gov.

Their work

Papers
45 (first author 1, last author 5)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
115
Papers, trials and grants by year

2010: 1 trial · 2011: 1 paper · 2012: 1 paper · 2013: 3 papers · 2014: none · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: 2 papers · 2020: 6 papers · 2021: 5 papers · 2022: 1 paper · 2023: 8 papers · 2024: 6 papers · 2025: 6 papers · 2026: 3 papers

Papers 45

  1. Circulating tumour DNA as a prognostic tool for surgically treated pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.humpath.2025.106024↗
  2. Stereotactic MRI-guided adaptive radiation therapy (SMART) for locally advanced pancreatic cancer: A prospective single-center cohort study. Co-author DOI 10.1016/j.radonc.2026.111790↗
  3. The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer. Co-author DOI 10.1016/s1470-2045(25)00714-4↗
  4. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  5. PANTAX: a phase Ib clinical trial of the efflux pump inhibitor SCO-101 in combination with gemcitabine and nab-paclitaxel in non-resectable or metastatic pancr… Co-author DOI 10.1007/s10637-025-01526-7↗
  6. Elevated levels of cleaved soluble forms of urokinase-type plasminogen activator receptor are associated with poor survival in advanced pancreatic cancer. Co-author DOI 10.1016/j.ejca.2025.116095↗
  7. Utility of peritoneal fluid for multiplexed mRNA profiling of peritoneal metastasis from pancreatic cancer. Co-author DOI 10.1016/j.prp.2025.156250↗
  8. Validation of the PANAMA Score for Survival and Benefit of Adjuvant Therapy in Patients With Resected Pancreatic Cancer after Neoadjuvant FOLFIRINOX. Co-author DOI 10.1097/sla.0000000000006650↗
  9. Promoter hypermethylation of SFRP1 is an allele fraction-dependent prognostic biomarker in metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fonc.2025.1568386↗
  10. Exploring the prognostic value of circular RNAs in pancreatic ductal adenocarcinoma using genome-wide expression profiling. Co-author DOI 10.1016/j.pan.2024.04.004↗
  11. Prognostic value of margin clearance in total and distal pancreatectomy specimens with pancreatic ductal adenocarcinoma in a Danish population-based nationwide… Co-author DOI 10.1016/j.prp.2023.155077↗
  12. Adaptive MRI-guided stereotactic body radiation therapy for locally advanced pancreatic cancer - A phase II study. Last author DOI 10.1016/j.radonc.2024.110347↗
  13. Efficacy and Safety of the Anti-IL1RAP Antibody Nadunolimab (CAN04) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Advanced/Metastatic Pan… Co-author DOI 10.1158/1078-0432.ccr-24-0645↗
  14. RNA expression profiling of peritoneal metastasis from pancreatic cancer treated with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC). Co-author DOI 10.1515/pp-2024-0001↗
  15. Prediction of overall survival in patients with locally advanced pancreatic cancer using longitudinal diffusion-weighted MRI. Co-author DOI 10.3389/fonc.2024.1401464↗
  16. Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. First author DOI 10.1016/j.annonc.2023.08.009↗
  17. Prognostic significance of margin clearance in pancreaticoduodenectomy specimens with pancreatic ductal adenocarcinoma in a Danish population-based nationwide … Co-author DOI 10.1016/j.hpb.2023.03.016↗
  18. High overall copy number variation burden by genome-wide methylation profiling holds negative prognostic value in surgically treated pancreatic ductal adenocar… Co-author DOI 10.1016/j.humpath.2023.11.002↗
  19. A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic c… Co-author DOI 10.1186/s12885-023-11035-6↗
  20. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. Co-author DOI 10.1200/jco.22.01134↗
  21. Surgical and Oncological Outcomes After Preoperative FOLFIRINOX Chemotherapy in Resected Pancreatic Cancer: An International Multicenter Cohort Study. Co-author DOI 10.1245/s10434-022-12387-2↗
  22. A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic c… Co-author DOI 10.21203/rs.3.rs-2955930/v1↗
  23. Radiotherapy for Locally Advanced Pancreatic Adenocarcinoma-A Critical Review of Randomised Trials. Last author DOI 10.3390/curroncol30070499↗
  24. Disparity in use of modern combination chemotherapy associated with facility type influences survival of 2655 patients with advanced pancreatic cancer. Co-author DOI 10.1080/0284186x.2021.2012252↗
  25. Pre-treatment serum vitamin D deficiency is associated with increased inflammatory biomarkers and short overall survival in patients with pancreatic cancer. Co-author DOI 10.1016/j.ejca.2020.10.038↗
  26. Response to the letter entitled: Re: Pre-treatment serum vitamin D deficiency is associated with increased inflammatory biomarkers and short overall survival i… Co-author DOI 10.1016/j.ejca.2021.09.009↗
  27. Gene expression profiling of morphologic subtypes of pancreatic ductal adenocarcinoma using surgical and EUS-FNB specimens. Co-author DOI 10.1016/j.pan.2021.01.025↗
  28. Patterns of Palliative Chemotherapy and Survival in Patients With Pancreatic Cancer Focusing on Age: A Nationwide Real-World Danish Registry Study. Co-author DOI 10.1097/mpa.0000000000001833↗
  29. Next-generation sequencing and histological response assessment in peritoneal metastasis from pancreatic cancer treated with PIPAC. Co-author DOI 10.1136/jclinpath-2020-206607↗
  30. Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment. Co-author DOI 10.1001/jamaoncol.2020.3537↗
  31. Clinical value of serum hyaluronan and propeptide of type III collagen in patients with pancreatic cancer. Co-author DOI 10.1002/ijc.32751↗
  32. Initial treatment and survival in 4163 Danish patients with pancreatic cancer: A nationwide unselected real-world register study. Co-author DOI 10.1016/j.ejca.2020.01.015↗
  33. Prognostic impact of Charlson's Age-Comorbidity Index and other risk factors in patients with pancreatic cancer. Co-author DOI 10.1111/ecc.13219↗
  34. Prognostic Value of Combined Detection of Serum IL6, YKL-40, and C-reactive Protein in Patients with Unresectable Pancreatic Cancer. Co-author DOI 10.1158/1055-9965.epi-19-0672↗
  35. Spatial and phenotypic characterization of pancreatic cancer-associated fibroblasts after neoadjuvant treatment. Co-author DOI 10.14670/hh-18-201↗
  36. Optimizing the management of locally advanced pancreatic cancer with a focus on induction chemotherapy: Expert opinion based on a review of current evidence. Co-author DOI 10.1016/j.ctrv.2019.05.007↗
  37. The effect of postoperative gemcitabine on overall survival in patients with resected pancreatic cancer: A nationwide population-based Danish register study. Co-author DOI 10.1080/0284186x.2019.1581374↗
  38. S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma. Last author DOI 10.1007/s00280-018-3528-5↗
  39. Peritoneal metastasis from pancreatic cancer treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC). Co-author DOI 10.1007/s10585-017-9849-7↗
  40. The potential diagnostic value of serum microRNA signature in patients with pancreatic cancer. Co-author DOI 10.1002/ijc.30291↗
  41. Characteristics, therapy and outcome in an unselected and prospectively registered cohort of pancreatic cancer patients. Last author DOI 10.1016/j.ejca.2012.07.017↗
  42. In reply to Parlak and Topkan. Re: Prognostic factors for survival and resection in patients with initial nonresectable locally advanced pancreatic cancer trea… Co-author DOI 10.1016/j.ijrobp.2012.06.001↗
  43. Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer. Co-author DOI 10.1371/journal.pone.0067059↗
  44. Prognostic factors for survival and resection in patients with initial nonresectable locally advanced pancreatic cancer treated with chemoradiotherapy. Last author DOI 10.1016/j.ijrobp.2011.09.008↗
  45. Feasibility of FDG-PET/CT imaging during concurrent chemo-radiotherapy in patients with locally advanced pancreatic cancer. Co-author DOI 10.3109/0284186x.2011.577095↗

Trials 1

  1. A Randomised Trial With Irinotecan, Cetuximab and Everolimus (ICE)Compared to Capecitabine and Oxaliplatin (CapOx) for Patients With Gemcitabin Resistant Pancr… Principal investigator NCT01042028↗

Closest collaborators

The 25 strongest of 115 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michael Bau Mortensen · 21 shared papers, 2011–2026 · strength 2.98
  2. Sönke Detlefsen · 16 shared papers, 2017–2026 · strength 2.72
  3. Claus Wilki Fristrup · 12 shared papers, 2019–2026 · strength 2.05
  4. Louise S. Rasmussen · 11 shared papers, 2019–2025 · strength 1.34
  5. Inna Markovna Chen · 9 shared papers, 2020–2025 · strength 1.15
  6. Julia Sidenius Johansen · 10 shared papers, 2013–2025 · strength 1.09
  7. Britta Weber · 7 shared papers, 2020–2024 · strength 1.07
  8. Mathilde Weisz Ejlsmark · 5 shared papers, 2018–2026 · strength 1.03
  9. Morten Bækbo Ladekarl · 7 shared papers, 2019–2025 · strength 0.95
  10. Astrid Zedlitz Johansen · 7 shared papers, 2020–2025 · strength 0.95
  11. Uffe Bernchou · 4 shared papers, 2023–2026 · strength 0.94
  12. Jon Kroll Bjerregaard · 11 shared papers, 2011–2021 · strength 0.78
  13. Carsten Palnæs Hansen · 7 shared papers, 2019–2025 · strength 0.76
  14. Faisal Mahmood · 3 shared papers, 2024–2026 · strength 0.73
  15. Martin Graversen · 4 shared papers, 2017–2025 · strength 0.70
  16. Trine Aaquist · 3 shared papers, 2023–2026 · strength 0.67
  17. Frank Viborg Mortensen · 4 shared papers, 2019–2026 · strength 0.56
  18. Anne Louise Højmark Bisgaard · 2 shared papers, 2024–2026 · strength 0.53
  19. Lukas Gammelgaard Rasmussen · 3 shared papers, 2021–2024 · strength 0.53
  20. Jorg H. Kleeff · 3 shared papers, 2020–2026 · strength 0.47
  21. Karin de Stricker · 2 shared papers, 2023–2026 · strength 0.43
  22. Rikke Løvendahl Eefsen · 2 shared papers, 2024–2025 · strength 0.43
  23. Sture Falkmer · 4 shared papers, 2020–2021 · strength 0.41
  24. Stine Brændegaard Winther · 3 shared papers, 2018–2023 · strength 0.41
  25. Ernesto Sparrelid · 2 shared papers, 2025–2026 · strength 0.40

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.